Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Evidence Gaps: Most positive findings come from topical formulations or small studies
Semaglutide GLP-1 has been shown to significantly reduce body weight, improve blood sugar control, and reduce waist circumference
BDI, Beck Depression Index
New England Journal of Medicine [Internet]
If pancreatitis is suspected, Wegovy should be discontinued and appropriate diagnostic tests performed urgently Gallbladder problems : Rapid weight loss increases risk of gallstone formation, with cholelithiasis reported in approximately 1.6% of Wegovy users Intestinal obstruction/ileus : Cases have been reported in post-marketing surveillance, particularly in patients with pre-existing GI conditions Management strategies recommended by healthcare professionals include: Eating smaller, more frequent meals rather than large portions Avoiding high-fat, spicy, or heavily processed foods Staying well-hydrated, particularly if experiencing diarrhoea or vomiting, to prevent dehydration and potential acute kidney injury Not lying down immediately after eating to minimise reflux Ensuring adequate fibre intake to prevent constipation Taking the medication on the same day each week to maintain steady levels Most GI side effects improve over time as the body adjusts to the medication, typically becoming less troublesome after 4-8 weeks at each dose level
The analysis shows that rTs24GST has fewer interactions compared to other complexes (Fig 6A), consistent with the lowest number of contacting residues showed in Fig 4
